JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: In Vitro Activity

In vitro activity of a new triazole antifungal agent, SCH56592, against clinical isolates of filamentous fungi.

In vitro activity of a new triazole antifungal agent, SCH56592, against clinical isolates of filamentous fungi. by Marco F, Pfaller MA, Messer SA and Jones RN published in Mycopathologia 1998; 141 (2): 73-77

In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.

In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. by Jones RN, Ballow CH, Schentag JJ, Johnson DM and Deinhart JA published in Diagn. Microbiol. Infect. Dis. 1998; 31 (1): 313-325

In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1,249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.

In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1,249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. by Jones RN, Biedenbach DJ, Croco MA and Barrett MS published in Diagn. Microbiol. Infect. Dis. 1998; 31 (4): 573-578

In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): A fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group.

In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): A fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group. by Jones RN and Erwin ME. published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 55-64

Comparative in vitro activity of alexomycin (U-82127) tested against Escherichia coli, Salmonella spp. and enterococci of animal and human origin.

Comparative in vitro activity of alexomycin (U-82127) tested against Escherichia coli, Salmonella spp. and enterococci of animal and human origin. by Jones RN, Chen YS and Marshall SA published in Clin. Microbiol. Infect. 1998; 4 (10): 601-603

In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin.

In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin. by Johnson DM and Jones RN. published in J. Antimicrob. Chemother. 1998; 42 (4): 555-557

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA, Erwin M and Ramirez-Rhonda C published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 113-119

In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.

In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp. by Croco MA, Biedenbach DJ, Pfaller MA, Doern GV, and Jones RN published in J. Antimicrob. Chemother. 1998; 42 (5): 672-673

In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): A novel orally administered streptogramin combination. The Quality Control Study Group.

In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): A novel orally administered streptogramin combination. The Quality Control Study Group. by Putnam SD, Jones RN and Johnson DM published in Diagn. Microbiol. Infect. Dis. 1997; 28 (3): 139-147

In vitro evaluation of contemporary β-lactam drugs tested against viridans group and β-haemolytic streptococci.

In vitro evaluation of contemporary β-lactam drugs tested against viridans group and β-haemolytic streptococci. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (4): 151-154

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world Wide. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1989; 28 (4): 157-163

In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample.

In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample. by Pfaller MA, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 273-276

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. by Jones RN, Barrett MS and Erwin ME published in Antimicrob. Agents Chemother. 1997; 41 (2): 488-493

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response.

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response. by Jones RN and Dudley MN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (1): 5-18

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. by Jamjian C, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (2): 454-459

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing.

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing. by Jamjian C, Barrett MS and Jones RN published in Diagn, Microbiol, Infect, Dis, 1997; 27 (4): 129-138

Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 Gram-negative bacteria.

Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 Gram-negative bacteria. by Gales AC, Pignatari AC, Jones RN, Baretta M and Sader HS published in Rev. Assoc. Med. Bras. 1997; 43 (2): 137-144

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin. by Erwin ME, Varnam D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (2): 93-100

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. by Ballow CH, Jones RN, Johnson DM, Deinhart JA, and Schentag JJ published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 173-186

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. by Baron EJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (3): 141-151

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes.

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes. by Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1995; 39 (7): 1636-1642

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results. by Jones RN, Sutton LD, Cantrell HF and Lankford RB published in Diagn. Microbiol. Infect. Dis. 1994; 20 (3): 143-149

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5,556 recent clinical isolates from five medical centers.

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5,556 recent clinical isolates from five medical centers. by Sader HS, Jones RN, Washington JA, Murray PR, Gerlach EH, Allen SD and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1993; 17 (2): 143-150

In vitro activity of 43 antimicrobial agents tested against ampicillin- resistant enterococci and Gram-positive species resistant to vancomycin.

In vitro activity of 43 antimicrobial agents tested against ampicillin- resistant enterococci and Gram-positive species resistant to vancomycin. by Yamane N and Jones RN published in Diagn. Microbiol. Infect. Dis. 1991; 14 (4): 337-345

Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Multicenter in vitro evaluation of SM-7338, a new carbapenem. by Jones RN, Aldridge KE, Allen SD, Barry AL, Fuchs PC, Gerlach EH and Pfaller MA published in Antimicrob. Agents Chemother. 1989; 33 (4): 562-565

In vitro studies of meropenem.

In vitro studies of meropenem. by Jones RN, Barry AL and Thornsberry C published in J. Antimicrob. Chemother. 1989; 24 (Suppl A): 9-29

Review of the in vitro spectrum of activity of imipenem.

Review of the in vitro spectrum of activity of imipenem. by Jones RN published in Am. J. Med. 1985; 78 (6A): 22-32